Bausch + Lomb introduces a preservative-free version of its Blink Triple Care eye drops. The product will be sold in major retailers including Amazon, CVS, Target, and Walgreens by the end of June 2026. This launch expands the brand’s portfolio of preservative-free eye care solutions.
Bausch + Lomb names **Thomas Appio** as interim CEO amid expectations of an upward revision to its full-year financial guidance. The appointment follows leadership changes at the eye-health company, which operates brands like Biotrue and Soflens. Analysts cite operational improvements and market demand as potential drivers for the revised outlook.
Bausch + Lomb reports positive phase 2 results for its dual-action lifitegrast/perfluorohexyloctane dry eye drop. The company also announces encouraging phase 1b findings for BL1332, a novel TRPV1 antagonist targeting ocular surface pain. Both therapies represent first-in-class treatments in their respective areas.
Bausch + Lomb appoints Thomas J. Appio as interim CEO after Brent Saunders leaves the company. This transition follows a mutual agreement between Saunders and Bausch Health, the parent company. Appio, currently holding a leadership role, will oversee Bausch + Lomb’s operations during this period.
